Clinical trials: SARS CoV 2 Virus
COVID-19, SARS-CoV-2 Infection
Whole-Virion Inactivated SARS-CoV-2 Vaccine (BBV152) for COVID-19 in Healthy Volunteers
Double blind, Multi-Centre study to evaluate the safety, reactogenicity, tolerability, and immunogenicity of three investigational vaccine groups and one placebo group in healthy volunteers who receive two intramuscular doses of…
- Trial name
- BBV152 (NCT04471519)
- Testing
- BBV152A - Phase I, BBV152B - Phase I, BBV152C - Phase I
- Where
- 12 sites in India
- Volunteers
- 755 people, healthy volunteers welcome
- Sponsor
- Bharat Biotech International Limited
Covid19, SARS CoV 2 Infection
Safety and Immunogenicity Study of Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Adult Healthy Volunteers (COVID-19)
This is a first-in-human, phase I/IIa, randomized, controlled, observer-blinded, dose-escalation, multicentre clinical trial to evaluate safety and immunogenicity of COVID-19 HIPRA vaccine in adult healthy volunteers.
- Trial name
- NCT05007509
- Testing
- COVID-19 vaccine HIPRA 10, COVID-19 vaccine HIPRA 20, COVID-19 vaccine HIPRA 40
- Where
- 2 sites in Spain
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Laboratorios Hipra, S.A.
Bioavailability
Relative Bioavailability Study of PF-07321332/Ritonavir Oral Powder Relative to the Commercial Tablets in Healthy Participants
The purpose of this study is to estimate the relative bioavailability of PF-07321332/ritonavir oral powder relative to the commercial tablet formulation under fasted condition in healthy adult participants.
- Trial name
- NCT05263921
- Testing
- PF-07321332/ritonavir
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
SARS-CoV-2, COVID-19
A Study of the Effectiveness of Moderna COVID-19 Vaccine
This is an observational cohort study to evaluate real-world vaccine effectiveness and durability of Moderna COVID-19 vaccine among a diverse population at Kaiser Permanente Southern California (KPSC).
- Trial name
- NCT05933304
- Where
- United States
- Volunteers
- 927,004 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
COVID-19, SARS-CoV-2 Infection
rSIFN-co Among Healthy Subjects and Subjects With Mild or Asymptomatic COVID-19
This is a phase II pilot, international, multicenter, randomized, double-blind, placebo-controlled study that aims to evaluate the safety and preliminary efficacy of rSIFN-co nasal spray in healthy subjects in close contact with…
- Trial name
- NCT05485584
- Testing
- rSIFN-co Nasal Spray
- Where
- 2 sites in Philippines
- Volunteers
- 188 people, healthy volunteers welcome
- Sponsor
- Sichuan Huiyang Life Science and Technology Corporation
COVID-19
Clinical Trial of Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Healthy Adults
This study is an open-label phase Ⅳ clinical trial of the inactivated SARS-CoV-2 vaccine(CoronaVac)manufactured by Sinovac Research \& Development Co., Ltd.
- Trial name
- NCT04962308
- Testing
- SARS-CoV-2 Inactivated Vaccine, The SARS-CoV-2 Inactivated Vaccine
- Where
- China
- Volunteers
- 1,400 people, healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
Long Covid19
Effectiveness of Testofen Compared to Placebo on Long COVID Symptoms
This is a double blind, randomised, placebo-controlled trial to evaluate orally-dosed Testofen (a specialised extract of Trigonella foenum-graecum (Fenugreek) seed) compared to placebo on post COVID-19 symptoms in otherwise…
- Trial name
- NCT05795816
- Testing
- Testofen, Microcrystalline cellulose
- Where
- Australia
- Volunteers
- 150 people
- Sponsor
- RDC Clinical Pty Ltd
SARS-CoV-2 Acute Respiratory Disease
A Prospective Virtual Study of Patient Reported Behaviors and Health Outcomes in Individuals With COVID-19
The primary objective of this study is to identify and describe patient behaviors and clinical outcomes among patients who have tested positive for mild to moderate COVID-19.
- Trial name
- NCT05042232
- Testing
- SARS-CoV-2 Positive, SARS-CoV-2 Negative
- Where
- United States
- Volunteers
- 239 people, healthy volunteers welcome
- Sponsor
- Everly Health
Post COVID-19 Condition, Post COVID-19 Condition (PCC)
Effects of Kneipp Hydrotherapy in Post-COVID-19 Patients
This randomized controlled study evaluates the effects of cold water hydrotherapy in patients with Post-COVID Syndrome. The primary aim is to assess changes in quality of life compared to an usual care setting without…
- Conditions
- Post COVID-19 Condition, Post COVID-19 Condition (PCC), Post COVID-19, Post COVID-19 Syndrome
- Trial name
- HydroCoVitalB (NCT07110714)
- Testing
- Cold water hydrotherapy
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Eggensberger OHG
SARS-CoV-2
Safety and Immunogenicity of Glycovax-002 Vaccine in Healthy Adults
Glycovax Pharma has developed a glycoconjugate vaccine candidate called Glycovax-002 to fight the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at the origin of COVID-19.
- Trial name
- NCT05799651
- Testing
- Glycovax-002
- Where
- Australia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Glycovax Pharma Inc.
COVID -19, COVID-19 (Prevention)
A Study Evaluating MDX2301 in Healthy Adults and Adults at Higher Risk for Severe COVID-19.
This first-in-human study is designed to evaluate the safety, tolerability, pharmacokinetics, anti-drug antibodies, and neutralizing activity of MDX2301 administered by intravenous (IV), intramuscular (IM), or subcutaneous (SC)…
- Trial name
- NCT07445971
- Testing
- MDX2301, Normal Saline
- Where
- 2 sites in United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- ModeX Therapeutics, An OPKO Health Company
Post-Acute COVID-19 Syndrome, Cognitive Impairment
Safety, Efficacy, and Dosing of VIX001 in Patients With Neurological Symptoms of Post Acute COVID-19 Syndrome (PACS).
The study, identified as VIX001-PACS-01, is a Phase 1, open-label, dose-escalation trial evaluating the safety, tolerability, preliminary efficacy, and dose effect of VIX001, an amniotic fluid product, in patients with Post-Acute…
- Conditions
- Post-Acute COVID-19 Syndrome, Cognitive Impairment, Neurological Complication
- Trial name
- NCT05947617
- Testing
- VIX001
- Volunteers
- 9 people
- Sponsor
- Neobiosis, LLC
Coronavirus Disease 2019 (COVID-19), Acute Lung Injury
Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure
This was a randomized, double-blind, placebo-controlled Phase 2/3 study to evaluate the safety and efficacy of dociparstat sodium in adult patients with acute lung injury (ALI) due to Coronavirus Disease 2019 (COVID-19).
- Conditions
- Coronavirus Disease 2019 (COVID-19), Acute Lung Injury, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
- Trial name
- NCT04389840
- Testing
- Dociparstat sodium
- Where
- 12 sites in United States
- Volunteers
- 27 people
- Sponsor
- Jazz Pharmaceuticals
COVID
Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease
The purpose of this adaptive trial is to determine the clinical efficacy of Ifenprodil in the treatment of patients infected with COVID-19.
- Trial name
- NCT04382924
- Testing
- NP-120 (Ifenprodil)
- Where
- 10 sites in United States, Australia and 2 more
- Volunteers
- 168 people
- Sponsor
- Algernon Pharmaceuticals
Severe Acute Respiratory Syndrome Coronavirus 2, Metabolic Syndrome
Metformin Glycinate in Patients With MS or DM2 , Hospitalized With COVID-19 and SARS Secondary to SARS-CoV-2
The purpose of this study is to evaluate the efficacy and safety of metformin glycinate at dose of 620 mg twice per day plus standard treatment comparing to standard treatment alone (we will use placebo) of patients who have…
- Conditions
- Severe Acute Respiratory Syndrome Coronavirus 2, Metabolic Syndrome, Type 2 Diabetes
- Trial name
- DMMETCOV19 (NCT04626089)
- Testing
- metformin glycinate
- Where
- Mexico
- Sponsor
- Laboratorios Silanes S.A. de C.V.
COVID-19, SARS-CoV-2 Infection
Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in Adults
This is a randomized, Phase 3 study comparing the immunogenicity and safety of 3 different lots of Novavax vaccine with Matrix-M™ adjuvant (NVX-CoV2373).The study will enroll approximately 900 previously vaccinated adults 18 to…
- Trial name
- NCT05463068
- Testing
- NVX-Cov2373
- Where
- 30 sites in United States
- Volunteers
- 911 people, healthy volunteers welcome
- Sponsor
- Novavax
SARS-CoV-2 Infection, Lung Fibrosis
Study to Assess Efficacy and Safety of Treamid for Patients With Reduced Exercise Tolerance After COVID-19
The innovative drug Treamid is planned for use in the treatment of patients with persistent lung damage and reduced exercise tolerance exertion after COVID-19 pneumonia in a multicenter, randomized, double-blind…
- Trial name
- NCT05516550
- Testing
- Treamid, Treamid twice a day, Treamid once a day
- Volunteers
- 412 people
- Sponsor
- PHARMENTERPRISES LLC
Covid19
KBP-201 COVID-19 Vaccine Trial in Healthy Volunteers
This is an First In Human (FIH), observer-blinded, randomized, placebo-controlled, parallel group study to evaluate the safety and immunogenicity of KBP-COVID-19 plus CPG adjuvant vaccine in healthy adult subjects in 2 age…
- Trial name
- NCT04473690
- Testing
- Low Dose of KBP-COVID-19, High Dose of KBP-COVID-19
- Where
- 8 sites in United States, Canada
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- KBio Inc
COVID-19
Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19)
The purpose of the study is to determine if a high dose of Intravenous Immune Globulin (IVIG) plus Standard Medical Treatment (SMT) can reduce all-cause mortality versus SMT alone in hospitalized participants with COVID-19…
- Trial name
- NCT04480424
- Testing
- GAMUNEX-C, Standard Medical Treatment
- Where
- 18 sites in United States
- Volunteers
- 100 people
- Sponsor
- Grifols Therapeutics LLC
Coronavirus Disease 2019 (COVID-19)
A Study to Learn About the Study Medicine Paxlovid (Nirmatrelvir + Ritonavir) in Adults Aged 60 and Older Living in Korean Long-term Care Hospitals Who Have COVID-19
The purpose of this study is to learn about the effects of the study medicine (called Paxlovid) for the possible treatment of COVID-19 in older adults who live in long-term care hospitals (LTCHs) in Korea.
- Trial name
- NCT07089680
- Testing
- Nirmatrelvir/Ritonavir
- Where
- 7 sites in South Korea
- Volunteers
- 937 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.